Abbvie , the Abbott spinoff that made its New York Stock Exchange debut at the start of the year, recently announced that its chief scientific officer will retire in the coming months. A new CSO has not yet been revealed, but is this something that investors need to watch? Can this appointment offer clues as to AbbVie's future strategy, much as a recent shake-up at Merck did? Health-care analyst Max Macaluso discusses this story in the following video.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article AbbVie Investors, Watch This Management Change originally appeared on Fool.com.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.